

The examiner further required an election of species if Group II were elected, as follows: wherein the PSGL-1-binding multimeric compound is (A) homomeric or (B) heteromeric; and wherein the homomeric or heteromeric PSGL-1-binding compound comprises (A) P-selectin (extracellular domain), (B) E-selectin (extracellular domain), (C) L-selectin (extracellular domain), or (D) an anti-PSGL-1 antibody. In response, Applicant has elected (A) homomeric PSGL-1-binding multimeric compound and (D) an anti-PSGL-1 antibody.

In item 2 on page 2 of the Restriction Requirement, the examiner invited Applicant to clarify whether the recitation "binds at least two PSGL-1 proteins" is intended to simply indicate that the multimeric compound [sic] binds two (2) PSGL-1 molecules or whether the claims encompass two types of PSGL-1 proteins (emphasis original). In response, Applicant submits these can but may not necessarily be mutually exclusive alternatives. Accordingly, Applicant respectfully refrains from making a clarification as invited by the examiner.

Dated: September 11, 2007

Respectfully submitted,

By 

Alan W. Steele, M.D., Ph.D.

Registration No.: 45,128

WOLF, GREENFIELD & SACKS, P.C.

Federal Reserve Plaza

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

(617) 646-8000